A pproximately 1 in 5 patients beyond the age of 45 years who experience acute myocardial infarction (MI) will be dead within a year. Although the incidence of ST-segment-elevation myocardial infarction (STEMI) has declined and survival after STEMI has improved, the prognosis remains poor for those with residual left ventricular (LV) dysfunction after STEMI. 
Acute MI causes myocardial necrosis and apoptosis resulting in ventricular remodeling, which is a precursor to subsequent cardiac dysfunction, congestive heart failure, and other cardiac adverse events (AEs), including death. 3, 4 The extent of myocardial cell loss is dependent on the duration and location of the coronary artery occlusion, existing collateral coronary circulation, and the integrity of the cardiac microvasculature. [5] [6] [7] [8] Evidence indicates that damage and ongoing attrition of the cardiac microcirculation are harbingers of worse outcome, and that recovery of microcirculatory function leads to improved LV function and clinical outcomes. 
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Mobilization of CD34+ cells from the bone marrow occurs naturally after MI. 10 Importantly, high levels of circulating CD34+ cells have been associated with improved outcomes in patients, while poor CD34+ mobilizers have a worse prognosis. 11, 12 CD34+ cells are capable of differentiating into endothelial cells and also secrete a variety of paracrine factors that promote neovascularization. [13] [14] [15] [16] After an extensive MI, the natural repair mechanism of mobilization and recruitment of CD34+ cells may be insufficient to prevent adverse remodeling. Consequently, new strategies are needed to limit or prevent cardiac dysfunction after acute MI and to alter the natural history of the disease in patients with inadequate innate repair mechanisms. 17, 18 Over 2600 patients have received intracoronary infusion of autologous bone marrow-derived mononuclear cells (BMMNCs) post MI. 19 While some studies of bone marrow cell therapy post-STEMI have shown significant improvements in cardiac function and reduction in major adverse cardiovascular events (MACE), 20, 21 others have not, 22 although the safety of this approach has been established. A meta-analysis of 50 BMMNC studies showed significant improvements in clinical outcomes, including increase in ejection fraction (EF, mean 4%) and reductions in infarct size, incidence of death, and recurrent MI. 23 The inconsistency of results from BMMNC infusion studies may reflect the fact that not all bone marrow cells contribute to tissue repair. 24, 25 Available evidence suggests that specific mononuclear cell subpopulations are integral to driving ischemic tissue repair. 26 Most evidence supports CD34+ cells as a critical factor in mediating repair, and preclinical data show that selected CD34+ cells provide superior outcomes when compared with unselected BMMNC, even at equivalent CD34+ cell doses. 27 A Phase 1, prospective, multicenter, dose-escalating cohort-controlled trial of intracoronary administration of bone marrow-derived autologous CD34+ cells in STEMI patients provided preliminary evidence of feasibility and safety and suggested that patients receiving ≥10 million CD34+ cells had significant improvement in myocardial perfusion and preservation of LV function at 6 months follow-up. 28 In the present PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled study), we aimed to further evaluate the safety and bioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in patients with residual LV dysfunction after STEMI.
Methods

Study Population and Design
PreSERVE-AMI is a Phase 2, randomized, double-blind, placebocontrolled trial performed at 60 sites in the United States. From January 2012 to December 2013, patients with LV dysfunction (EF≤48% by cardiac magnetic resonance [CMR] imaging) ≥4 days after coronary artery stenting were enrolled after providing institutional review board-approved informed written consent. Time from symptom onset to patient receiving coronary artery stent is referred to as total ischemic time. Enrolled subjects underwent mini bone marrow harvest and were randomized 1:1 to receive either autologous CD34+ cells (minimum dose of 10 million [±20%] CD34+ cells in autologous serum) or autologous serum by intracoronary infusion. What Is Known?
Nonstandard Abbreviations and Acronyms
• Benefits of intracoronary administration of bone marrow mononuclear cells in patients after acute myocardial infarction (MI) remain uncertain.
• We investigated whether high-dose autologous bone marrow-derived CD34+ cells will improve outcomes post MI.
What New Information Does This Article Contribute?
• This PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) showed that intracoronary autologous CD34+ cell therapy is safe after MI and may reduce adverse outcomes and improve function, especially in those receiving higher cell doses.
Autologous bone marrow mononuclear cell therapy has been used in patients with left ventricular dysfunction post acute MI. However, its beneficial effects remain uncertain. We conducted a Phase 2, randomized, blinded, placebo-controlled trial to investigate whether intracoronary administration of high doses of autologous bone marrow CD34+ cells, known to be enriched for progenitor cells, will be safe and efficacious in patients with left ventricular dysfunction after an acute MI. We found that CD34+ cell therapy was safe. In secondary measures, mortality was lower and there was a dose-dependent increase in left ventricular function and reduction in infarct size in the treated group compared with placebo.
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The primary safety end point was occurrence of AEs, serious adverse events (SAEs), and MACE (cardiovascular mortality, heart failure, reinfarction, and revascularization). The primary efficacy end point was change in resting myocardial perfusion over 6 months (gated single-photon emission computed tomography [SPECT] ). The initial study design included a primary safety end point that was restricted to evaluating the safety of bone marrow harvest and infusion; however, this was modified during the course of the study to reflect the goal of assessing overall safety. Secondary end points, including changes in LVEF, LV end-systolic volume, LV end-diastolic volume, and infarct size (by CMR; Online Data Supplement).
Bone Marrow Harvest and Cell Selection
Bone marrow aspiration was performed in all subjects randomized to either CD34+ cells or placebo between 4 and 9 days after stent implantation using conscious sedation and local anesthesia (Online Data Supplement). CD34+ cells were selected from the harvested cells using the CliniMACS system. CD34+ cell enumeration, purity, and viability were assayed by flow cytometry (Stem-Kit reagents; Beckman Coulter, Brea, CA). Endotoxin levels were determined using Limulus test kits (Lonza, Allendale, NJ). The CD34+ cell product was suspended in 10 mL phosphate-buffered saline supplemented with autologous serum and human serum albumin. All treatment subjects received a minimum dose of ≥10 million (±20%) CD34+ cells as defined in release criteria. The cell dose in each subject was the total dose of CD34+ cells produced from their bone marrow aspirate. Control subjects received 10 mL phosphate-buffered saline supplemented with autologous serum and human serum albumin without cells.
Cell Infusion
Subjects were infused within 72 hours of completion of the bone marrow harvest and within 11 days after stent placement. CD34+ cells were infused via an over-the-wire balloon catheter positioned within the stented segment of the infarct-related artery using a stop-flow technique described previously 28 (Online Data Supplement).
Imaging
CMR was performed to assess baseline LVEF if a screening echocardiogram LVEF (or equivalent) performed at least 2 days after percutaneous coronary intervention revealed an LVEF ≤45% (or ≤35% if assessed before day 2). The CMR LVEF was performed no sooner than 96 hours (4 days) after stenting and had to be ≤48% to be eligible for randomization. For subjects who could not undergo CMR (eg, implanted device), the LVEF was measured with SPECT and had to be ≤45%. Follow-up was also performed with SPECT in these subjects. At 6-month follow-up, LVEF, LV end-systolic volume, LV enddiastolic volume, and infarct size were assessed by CMR (SPECT substituted in subjects who could not undergo CMR). A gated rest SPECT scan was used to evaluate perfusion using the resting total severity score. Approximately 25% of paired scans (CMR and SPECT) were reread by the reader to assess reproducibility. In addition, both the SPECT and CMR studies were reread by independent core laboratories. Although there was disparity between the core laboratory readings on the individual subject level, the overall conclusions from the 2 core laboratories were similar. Accordingly, the original core laboratory results are reported here.
Safety Monitoring
Safety was assessed by monitoring of AEs, SAEs, MACE, temperature log, physical examinations with vital signs and weight, cardiopulmonary examination, 12-lead ECGs, 24-hour Holter ECG monitoring (after the infusion was completed), and laboratory safety assessments (biochemistry, hematology, coagulations status, and cardiac markers). An AE was defined as any untoward medical occurrence in a subject and could include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated). A Clinical Endpoint Committee, blinded to randomized treatment assignments, was appointed to independently Figure 1 . PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) study flow diagram. †There were no deaths in the modified intention to treat (mITT) treatment group. *There were 3 deaths in the mITT placebo group. ¥Other reasons were AIDS, low hemoglobin values, hypotension requiring medication, reocclusion of the infarct-related artery, pulmonary nodules, apical thrombus, cardiac magnetic resonance (CMR) not being performed and subject lost before treatment. AE indicates adverse event; ITT, intent-totreat, LVEF, left ventricular ejection fraction; SPECT, single-photon emission computed tomography; and STEMI, ST-segment-elevation myocardial infarction.
adjudicate investigator-reported MACE and other events of interest (Online Data Supplement). The study was monitored by an independent Data Safety Monitoring Board.
Statistical Design Analysis
Using a 2-sample t test at a 2-sided 0.05 level of significance, a sample size of 80 subjects in each group was determined to yield 85% power to reject the hypothesis that there is no difference between the 2 groups in the change in resting total severity score, after allowance for a 5% drop out. During the course of the study, the Contract Research Organization was instructed to perform an unblinded analysis to determine if sample size would be sufficient to distinguish a change in LVEF between treatment and control groups. They reported that the sample size would be insufficient and in fact that the change in LVEF favored the control group at that point. Data are expressed as mean±SD, and confidence intervals are 2-sided and at the 95% confidence level, unless otherwise stated. The primary efficacy analyses for mean change in perfusion (resting total severity score) from baseline to 6 months between the treatment and control groups and for secondary end points of changes in LVEF were performed using the ANCOVA and the baseline values as covariates. The primary safety comparison was for differences in the rates of AE, SAE, and MACE between groups for the composite and individual MACE using a χ 2 test and 2-sample z test, as appropriate. Prespecified tertiary analyses to assess the influence of multiple parameters, including cell dose and total ischemic time, on efficacy and safety end points were performed using multiple regression models and ANCOVA. Responses in cell dose subgroups of <14, >14, and >20 million cells/kg were assessed in a post hoc analysis that evaluated the ratio of MACE. Analyses on the intention to treat (defined as all randomized subjects) or modified intention to treat (defined as all randomized subjects who underwent bone marrow harvest and were infused with study product) are reported.
Results
Subject Disposition and Baseline Characteristics
Of the 281 subjects consented, 86 failed screening, and the remaining 195 were randomized to either the CD34+ cell therapy group (N=100) or the placebo group (N=95) (Figure 1 ). Of those randomized, 161 subjects (78 in the treated and 83 in the control group) completed the bone marrow harvest procedure and underwent infusion. All surviving subjects have completed the 1-year follow-up visit (median follow-up time, 18 months at the time of the analysis for this article).
Baseline characteristics of treated subjects were similar between the cell therapy and placebo groups in terms of sex, race, cardiovascular risk factors, and medical history. Index primary percutaneous coronary intervention parameters were similar with the exception of total ischemic time of the infarctrelated artery, which was significantly longer in the CD34+ cell group compared with the control group (P=0.04; Table 1 ). When divided into groups of CD34+ cell dose administered, no differences in baseline characteristics were observed across groups (Online Table I ).
Bone Marrow Harvest and Coronary Infusion Procedure
Bone marrow harvest (mean volume, 388±18 mL) yielded total mean viable CD34+ cell count of 41.3±21.5 million and 40.2±25.9 million in the control and treatment groups, respectively (Online Table II ). The mean CD34+ cell count in the final cell product (CLBS10) was 14.9±8 million cells (range 8-43.8 million cells). The mini bone marrow harvest procedure and infusion were well tolerated, with 5% and 9% of subjects, respectively, experiencing SAEs not considered related to the procedures (Online Table III) .
SPECT Perfusion Imaging
The mean resting total severity score, the primary end point of the study, improved between baseline and 6 months in both the control (−149.6±221.16; P=0.01) and cell therapy (−142.7±257.8; P=0.014; Figure 2A ) groups; however, this change was not significantly different between the groups. There was no relationship between cell dose and improvement in perfusion in further analyses.
Postinfusion Clinical Events
Mortality and MACE
In the modified intention to treat population (all randomized subjects who underwent bone marrow harvest and were infused with study product), there were no deaths in the CD34+ cell group compared with 3 deaths in the control group (P=0.04, z test) with trends in the probability of survival favoring the CD34+ cell group (P=0.055; Figure 3A) . Deaths occurred at postinfusion day 3, 22, and 695 because of ventricular fibrillation, cardiogenic shock, and heart failure, respectively. In the intention to treat population (all randomized subjects), 3 deaths occurred in subjects randomized to the control group, and 1 death occurred in a subject randomized to CD34+ cell treatment who did not undergo infusion (Online Figure I) . Although the incidence of MACE was similar in the CD34+ cell and control groups (Online Table III ), a regression analysis adjusting for total ischemic time showed a trend toward decreased MACE incidence as the CD34+ cell dose increased (P=0.06; Table 2 ). As a result, post hoc analyses were performed to determine cell dose thresholds above and below which an impact on MACE was observed. A trend toward a reduced MACE incidence in the >14 and >20 million cell dose subgroups was observed but was not statistically significant ( Figure 3B ).
Safety
The incidence of AEs and SAEs at 12-month follow-up (18-month median follow-up) was similar in the cell therapy and control groups (Online Table III ). When adjusted for total ischemic time, increasing CD34+ cell dose was associated with increased number of days alive and out of the hospital (P=0.05; Table 2 ).
LV Function
A statistically significant increase in LVEF from baseline to 6 months was observed within the CD34+ cell group (P<0.001) and within the control group (P<0.001; Figure 2B ). Although there was not a difference in LVEF change from baseline between the control group and CD34+ cell group as a whole, tertiary analyses demonstrated a significant association between the change in LVEF and cell dose after adjusting for total ischemic time (P=0.045; Table 2 ). Post hoc analyses of cell dose subgroups showed that the LVEF change in those receiving CD34+ cell doses >20 million cells (10.2±9.8%) was significantly greater compared with the control group (4.9±8.8%) (P<0.05; Figure 2C ). There did not seem to be an association between changes in LV end-systolic volume and LV end-diastolic volume and CD34+ cell dose (Table 2) .
Infarct Size
The mean LV infarct size decreased from baseline to 6 months in both the control (−24±52%; P<0.001) and the cell therapy (−23±34%; P<0.001) groups; however, this change was not significantly different between the groups ( Figure 2D ). Tertiary analyses showed that CD34+ cell dose was associated with reduction in infarct size (P=0.02) after adjustment for total ischemic time ( Table 2) . Post hoc analyses showed nonsignificant trends toward greater percent reductions in infarct size at the >14 million and >20 million cell doses ( Figure 2D ).
Relationship Between Bone Marrow CD34+ Cell Content and Clinical Outcomes
Bone marrow CD34+ cell content was not associated with differences in baseline characteristics, except for the prevalence of diabetes mellitus being increased among patients with higher bone marrow CD34+ count (Online Table IV) . Bone marrow CD34+ cell content did not correlate with the rates of MACE (P=0.2) or SAEs (P=0.4; Tables 3 and 4) .
Discussion
This Phase 2 study demonstrates that intracoronary infusion of CD34+ cells after STEMI is associated with favorable safety and clinical outcomes. Although the primary efficacy end point of improvement in resting myocardial perfusion over 6 months was not met, this study provides new insight into the influence of administered CD34+ cell dose on clinical safety and efficacy outcomes. When adjusted for ischemic time, there was a significant relationship between the CD34+ cell dose received and the change in infarct size, LVEF, and days alive and out of hospital. The lack of mortality among active treatment subjects is also noteworthy. The low mortality rates observed in both the control (3.6%) and the CLBS10 treatment (0%) group may reflect both the clinical success of guideline-driven STEMI treatment and the CD34 therapy protocol.
Infarct size reduction tended to be greater with higher cell doses, and patients treated with >20 million cells showed greater LVEF change. The infarct region perfusion improvement that was observed in the Phase 1 study for subjects treated with ≥10 million cells was not observed in this Phase 2 study. Although perfusion was significantly improved from baseline to 6 months within both the control-and CLBS10-treated group, no difference between the 2 groups was found. These results indicate that an imaging-based end point such as SPECT myocardial perfusion may not be a suitable surrogate because of the limitations in reproducibility of the technique (eg, image acquisition and processing involving patient motion, filtering, collimation, alignment, and scaling). 29 Although our findings confirm the earlier Phase 1 safety profiles, longer follow-up is needed particularly with respect to cell dose threshold-related outcomes.
Failure to promptly revascularize after STEMI increases myocardial necrosis and may result in ventricular dilatation and progressive congestive heart failure. 30, 31 Despite the success of early thrombolysis and primary percutaneous coronary intervention in the management of STEMI, patients continue to be at risk for mortality and morbidity hazards because of persistent heart failure. 32, 33 There is evidence that microvascular abnormalities in this population may contribute to late complications despite epicardial revascularization, but few therapeutic options have been available to date. In response to MI, bone marrow-derived CD34+ cells are thought to be recruited into the circulation, to home to ischemic tissues, and to participate in the repair and regeneration process. However, this mechanism is not sufficiently beneficial in patients who develop congestive heart failure post MI.
Recent findings from the cell-based cardiac studies (ACCRUE) show that unselected BMMNCs may be ineffective for treatment of MI without measurable clinical benefit or changes in LV function. 22 This study supports the concept that focused therapy with a specific active agent cell type, administered at a specific concentration, may be a more effective therapeutic strategy. Preclinical models have already established that compared with the unselected BMMNC population, CD34+ cells more efficiently incorporate into the ischemic myocardium and increase capillary density. 27, 34 Clinical studies evaluating the therapeutic potential of cells selected for CD34 expression have also demonstrated a consistently favorable impact on outcomes. [35] [36] [37] [38] In each of the previous 5 randomized, placebo-controlled clinical trials of CD34 cell therapy, observations were made of superior safety and clinical benefit in the treated versus control subjects. 28, 35, 37, 39, 40 In this context, this study is consistent with the evidence for CD34 cell therapy safety and efficacy and supports further exploration of the CD34 therapeutic strategy.
The results of this PreSERVE-AMI Phase 2 study provide support for the concept that autologous administration of bone marrow CD34+ cells is safe. In addition, exploratory analysis indicates potential efficacy benefit at higher cell doses in patients with STEMI. Such hypothesis should be examined in future randomized controlled trials. Our findings mirror previous studies in refractory angina, critical limb ischemia, and heart failure. In addition, our study offers insights into the CD34+ cell dose threshold that is required for meaningful clinical efficacy.
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